Aktiesnakken — Juni 2013
-
han har 0-værdi på øvrig pipeline og duo/hexa
-
Seattle Genetics Inc. (SGEN) has struck a new antibody-drug conjugate
collaboration with Bayer AG (BAYN.XE, BAYRY) under which the German health-care
company will pay up to $520 million in connection with its use of Seattle
Genetics auristatin-based drug technology. -
høh - iflg frank er den nul værd. Bayer har dummet sig
-
hvad får dig til at tro, at FF har en kugleramme?
-
Interessant med den ADC deal. Det vil være forrygende, hvis vi kan brede indikationerne lidt ud
-
haha - problemet med FF er ikke at han ikke kan regne. Problemet er, at han ikke kan stille regnestykket op
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
